hct
recipi
virolog
confirm
rsv
infect
januari
januari
includ
studi
clinic
data
collect
databas
supplement
review
medic
record
studi
approv
institut
review
board
fred
hutchinson
cancer
research
center
subject
sign
inform
consent
permit
use
data
research
subject
incomplet
data
supplement
oxygen
use
follow
diagnosi
rsv
infect
exclud
institut
standard
practic
evalu
lower
respiratori
tract
diseas
hct
recipi
rsv
detect
upper
respiratori
tract
patient
consid
rsv
urti
upper
respiratori
tract
sampl
test
posit
rsv
rsvposit
lrti
specimen
radiograph
abnorm
patient
consid
rsv
lrti
rsvposit
lower
respiratori
tract
sampl
ie
bronchoalveolar
lavag
bal
lung
biopsi
specimen
autopsi
specimen
without
radiograph
abnorm
defin
proven
probabl
lrti
respect
rsvposit
upper
respiratori
tract
sampl
radiograph
abnorm
defin
possibl
lrti
day
rsv
lrti
diagnosi
defin
date
rsv
detect
lower
respiratori
tract
specimen
case
provenprob
lrti
date
radiograph
abnorm
detect
case
possibl
lrti
virolog
confirm
obtain
direct
fluoresc
antibodi
test
shell
vial
centrifug
convent
viral
cultur
lower
respiratori
tract
sampl
patient
also
rsv
detect
revers
chain
reaction
pcr
analysi
subject
divid
group
group
compris
patient
urti
present
without
progress
lrti
group
compris
patient
urti
present
subsequ
progress
proven
probabl
possibl
lrti
group
compris
patient
proven
probabl
possibl
lrti
present
maximum
supplement
oxygen
use
per
period
record
day
follow
initi
rsv
present
well
day
follow
lrti
diagnosi
supplement
oxygen
use
defin
deliveri
oxygen
modal
includ
nasal
cannula
mask
noninvas
posit
pressur
ventil
mechan
ventil
record
sustain
hour
supplement
oxygen
administ
context
medic
administr
baselin
supplement
oxygen
use
record
supplement
oxygen
administ
per
standard
clinic
nurs
protocol
center
supplement
day
defin
period
subject
receiv
l
supplement
oxygen
per
minut
sustain
continu
period
patient
aliv
impact
death
number
supplement
day
evalu
use
definit
definit
day
death
subsequ
day
day
follow
present
consid
supplement
oxygenfre
day
definit
subject
die
none
day
consid
supplement
day
ie
number
supplement
day
patient
analyz
basi
first
episod
rsv
follow
hct
present
progress
lrti
addit
analys
conduct
begin
time
lrti
diagnosi
probabl
overal
surviv
estim
use
kaplanmei
method
logrank
test
use
compar
mortal
curv
group
cox
proport
hazard
regress
use
evalu
unadjust
adjust
hazard
ratio
hr
time
first
use
supplement
oxygen
time
mechan
ventil
covari
evalu
candid
risk
factor
inclus
multivari
model
list
tabl
select
priori
variabl
p
valu
univari
analysi
candid
multivari
model
retain
model
remain
signific
modifi
effect
anoth
factor
confound
median
number
supplement
day
aliv
compar
among
group
within
group
divid
possibl
lrti
versu
provenprob
lrti
wilcoxon
rank
sum
test
twosid
p
valu
consid
statist
signific
sampl
size
estim
calcul
use
pearson
test
mortal
day
test
number
supplement
day
day
power
statist
analys
perform
use
sa
window
sa
institut
cari
nc
identifi
hct
recipi
rsv
infect
median
age
transplant
receipt
year
rang
year
median
time
initi
diagnosi
rsv
infect
follow
transplant
day
interquartil
rang
iqr
day
patient
present
urti
progress
lrti
group
progress
lrti
group
thirtythre
subject
present
lrti
group
comparison
demograph
variabl
group
shown
tabl
patient
develop
present
lrti
infect
defin
possibl
lrti
infect
defin
probabl
proven
lrti
probabl
case
identifi
whole
cohort
percentag
subject
use
l
supplement
oxygen
per
minut
diagnosi
compar
among
group
tabl
found
highest
present
lrti
group
group
patient
requir
mechan
ventil
diagnosi
proport
patient
requir
supplement
l
oxygen
per
minut
day
diagnosi
rsv
infect
lowest
patient
present
urti
group
highest
among
present
lrti
group
tabl
cumul
incid
curv
figur
patient
present
lrti
like
requir
supplement
oxygen
mechan
ventil
patient
present
urti
p
p
respect
logrank
test
lrti
diagnosi
need
supplement
l
oxygen
per
minut
mechan
ventil
day
higher
subject
present
lrti
progress
urti
respect
group
vs
respect
group
comparison
patient
possibl
lrti
versu
provenprob
lrti
group
show
higher
need
supplement
oxygen
use
vs
higher
need
mechan
ventil
vs
patient
provenprob
lrti
versu
possibl
lrti
cumul
incid
curv
figur
supplement
oxygen
use
mechan
ventil
time
lrti
significantli
higher
patient
provenprob
lrti
possibl
lrti
p
p
respect
logrank
test
risk
factor
time
first
use
supplement
oxygen
evalu
univari
mode
among
patient
time
initi
diagnosi
supplementari
tabl
variabl
evalu
age
transplant
lrti
timedepend
variabl
steroid
use
week
prior
diagnosi
rsv
infect
pcr
use
test
platform
associ
outcom
multivari
model
tabl
variabl
except
pcr
test
method
remain
signific
risk
factor
supplement
oxygen
use
risk
factor
mechan
ventil
also
evalu
univari
multivari
model
lrti
timedepend
risk
factor
remain
signific
supplementari
tabl
median
number
supplement
day
associ
interquartil
rang
aliv
per
definit
shown
figur
median
number
supplement
day
urti
diagnosi
patient
group
iqr
day
group
patient
provenprob
lrti
aliv
free
supplement
oxygen
use
median
day
less
group
initi
diagnosi
vs
day
p
analysi
group
start
lrti
indic
number
supplement
day
significantli
influenc
lrti
defin
group
patient
possibl
lrti
significantli
supplement
day
patient
probableproven
lrti
day
iqr
day
vs
day
iqr
day
p
subject
die
day
supplement
day
period
thu
calcul
supplement
day
per
definit
chang
median
group
supplementari
tabl
death
occur
patient
group
respect
day
follow
lrti
tabl
kaplanmei
curv
mortal
subject
time
initi
diagnosi
urti
group
lrti
group
shown
figur
curv
differ
significantli
p
logrank
test
curv
mortal
time
lrti
diagnosi
group
shown
figur
differ
note
patient
lrti
whether
progress
urti
present
lrti
p
logrank
test
figur
frequenc
death
howev
influenc
definit
lrti
death
among
patient
defin
possibl
lrti
death
observ
group
patient
probabl
proven
lrti
tabl
figur
given
mortal
rate
observ
cohort
potenti
supplement
day
consid
relev
endpoint
clinic
trial
enrol
patient
develop
rsv
lrti
evalu
differ
sampl
size
requir
mortal
supplement
day
endpoint
tabl
provid
sampl
size
estim
compar
mortal
number
supplement
day
day
subject
develop
present
provenprob
lrti
provenprob
group
base
baselin
mortal
rate
subject
provenprob
lrti
reduct
conserv
estim
mortal
rate
would
requir
sampl
size
subject
per
arm
type
error
power
contrast
conserv
increas
number
supplement
day
observ
mean
number
supplement
day
patient
provenprob
lrti
would
requir
subject
per
arm
addit
sampl
size
calcul
less
conserv
chang
mortal
number
supplement
day
shown
tabl
similarli
lower
sampl
size
requir
supplement
day
endpoint
present
studi
establish
clinic
outcom
includ
mortal
supplement
day
significantli
wors
hct
recipi
rsv
detect
lower
respiratori
tract
ie
probableproven
lrti
patient
rsv
detect
upper
respiratori
tract
ie
urti
possibl
lrti
death
due
caus
occur
patient
provenprob
lrti
also
demonstr
signific
reduct
number
supplement
day
patient
provenprob
lrti
compar
possibl
lrti
data
support
use
supplement
day
potenti
clinic
endpoint
could
associ
signific
reduct
sampl
size
rsv
infect
hct
recipi
histor
associ
signific
mortal
death
rate
patient
lrti
howev
mortal
rate
declin
presum
chang
transplant
practic
declin
use
myeloabl
regimen
improv
support
care
practic
addit
previou
studi
rsv
hct
recipi
use
differ
definit
lrti
may
account
wide
variat
endpoint
includ
progress
lrti
supplement
oxygen
use
mortal
current
guidelin
also
includ
possibl
lrti
recommend
manag
rsv
furthermor
differ
exist
among
transplant
center
use
bal
diagnos
lrti
due
respiratori
virus
present
studi
sought
character
clinic
outcom
clinic
statu
time
present
care
ie
urti
group
urti
progress
lrti
group
lrti
group
site
virolog
detect
urti
possibl
lrti
probabl
lrti
proven
lrti
found
substanti
differ
supplement
oxygen
use
number
supplement
day
mortal
subject
without
rsv
detect
lower
respiratori
tract
data
demonstr
subject
possibl
lrti
requir
littl
supplement
oxygen
death
similar
subject
urti
regardless
initi
present
convers
patient
provenprob
lrti
subject
die
significantli
higher
use
supplement
oxygen
data
consist
previou
studi
evalu
parainfluenza
viru
lrti
hct
recipi
outcom
possibl
lrti
case
significantli
better
provenprob
lrti
case
taken
togeth
data
suggest
less
conserv
approach
defin
lrti
without
determin
whether
rsv
truli
lower
respiratori
tract
case
imag
find
abnorm
may
clinic
mislead
contribut
find
mortal
rate
appear
decreas
among
patient
diagnosi
rsv
lrti
number
supplement
day
endpoint
also
evalu
current
studi
supplement
oxygen
use
correl
acut
lung
injuri
turn
associ
mortal
hct
recipi
addit
supplement
oxygen
use
typic
requir
hospit
thu
number
supplement
day
repres
composit
endpoint
take
account
diseas
sever
need
hospit
mortal
data
show
signific
decreas
supplement
day
subject
lrti
compar
urti
decreas
seen
subject
provenprob
lrti
compar
possibl
lrti
ventilatorfre
day
first
defin
introduc
ardsnet
schoenfeld
et
al
use
end
point
extens
intens
care
unit
literatur
sever
studi
includ
random
control
trial
limit
studi
viral
infect
enterovirus
influenza
viru
herp
virus
critic
ill
patient
sinc
use
end
point
definit
supplement
day
consist
schoenfeld
origin
definit
ventilatorfre
day
acut
respiratori
distress
syndrom
notabl
except
first
given
low
rate
mechan
ventil
cohort
overal
studi
suffici
power
evalu
ventilatorfre
day
thu
evalu
supplement
day
gener
patient
receiv
l
supplementari
oxygen
per
minut
requir
hospit
admiss
thu
increas
number
supplement
day
still
repres
signific
healthcar
cost
save
second
effect
death
evalu
tradit
definit
wherein
death
point
period
give
score
supplement
day
subject
definit
allow
day
prior
death
supplement
oxygen
use
count
supplement
day
second
definit
use
given
high
level
compet
risk
death
transplant
recipi
ultim
subject
supplement
day
prior
death
thu
mean
median
supplement
day
vari
greatli
use
either
definit
number
supplement
day
significantli
differ
among
subject
base
initi
present
group
well
classif
lrti
possibl
vs
provenprob
figur
lowest
median
number
supplement
day
occur
patient
present
provenprob
lrti
day
follow
subject
provenprob
lrti
regardless
present
day
contrast
subject
possibl
lrti
either
group
median
supplement
day
subject
urti
data
along
mortal
outcom
outlin
suggest
prognosi
hct
recipi
rsv
detect
upper
respiratori
tract
radiograph
abnorm
requir
sampl
lower
respiratori
tract
eg
bal
determin
whether
proven
lrti
present
confirm
rsv
lrti
bal
provid
use
prognost
inform
may
help
stratifi
patient
risk
help
priorit
expens
intens
therapeut
option
current
ribavirin
antivir
avail
specif
treatment
rsv
diseas
howev
cost
remain
prohibit
barrier
use
estim
cost
greater
cours
risk
stratif
base
confirm
probableproven
lrti
may
assist
treatment
consider
hct
recipi
rsv
addit
sever
antivir
phase
trial
treatment
rsv
infect
variou
popul
includ
hct
recipi
risk
stratif
may
help
develop
ration
prevent
treatment
strategi
immunocompromis
patient
agent
base
outcom
data
current
studi
calcul
estim
sampl
size
requir
compar
mortal
rate
number
supplement
day
day
endpoint
subject
provenprob
lrti
tabl
supplement
day
potenti
significantli
reduc
per
arm
sampl
size
compar
tradit
mortal
endpoint
could
potenti
aid
design
clinic
trial
feasibl
sampl
size
maintain
clinic
relev
endpoint
common
critic
use
ventilatorfre
day
endpoint
lack
consensu
definit
high
level
heterogen
thu
make
comparison
among
studi
difficult
firsttim
supplement
day
evalu
rsv
infect
hct
recipi
singl
center
studi
studi
implement
strict
criteria
evalu
need
supplement
oxygen
appli
consist
definit
need
addit
accur
diagnosi
provenprob
lrti
may
also
play
signific
role
enrich
clinic
trial
recruit
patient
like
experi
advers
outcom
thu
also
reduc
sampl
size
studi
sever
limit
first
retrospect
review
use
bal
evalu
lrti
larg
base
protocol
center
recommend
bal
rsv
detect
upper
respiratori
tract
radiograph
abnorm
present
howev
decis
pursu
bronchoscopi
ultim
left
attend
physician
thu
potenti
probabl
proven
case
may
miss
despit
inher
limit
captur
provenprob
lrti
case
demonstr
differ
clinic
outcom
group
addit
definit
supplement
day
one
supplement
l
oxygen
per
minut
requir
reli
subject
clinic
decis
may
physiolog
correl
howev
requir
sustain
period
without
use
l
supplement
oxygen
per
minut
deem
supplement
day
account
inher
variabl
conclus
data
demonstr
patient
rsv
detect
lower
respiratori
tract
ie
provenprob
lrti
wors
outcom
patient
rsv
detect
upper
respiratori
tract
despit
presenc
radiograph
abnorm
ie
possibl
lrti
separ
lrti
group
could
use
futur
outcom
research
howev
valid
result
site
protocol
import
one
potenti
applic
would
crossvalid
immunodefici
score
index
suggest
use
hct
recipi
rsv
infect
help
develop
consensu
definit
furthermor
use
conserv
approach
defin
lrti
implement
supplement
day
surrog
clinic
endpoint
believ
clinic
trial
may
abl
use
smaller
sampl
size
therebi
facilit
morerapid
develop
novel
agent
treat
rsv
infect
hct
recipi
